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Abstract
Background: Preclinical models of non-small cell lung cancer (NSCLC) require better clinical relevance to study disease
mechanisms and innovative therapeutics. We sought to compare and refine bioluminescent orthotopic mouse models of
human localized NSCLC.
Methods: Athymic nude mice underwent subcutaneous injection (group 1-SC, n=15, control), percutaneous orthotopic
injection (group 2-POI, n=30), surgical orthotopic implantation of subcutaneously grown tumours (group 3-SOI, n=25), or
transpleural orthotopic injection (group 4-TOI, n=30) of A549-luciferase cells. Bioluminescent in vivo imaging was then
performed weekly. Circulating tumour cells (CTCs) were searched using CellsearchH system in SC and TOI models.
Results: Group 2-POI was associated with unexpected direct pleural spreading of the cellular solution in 53% of the cases,
forbidding further evaluation of any localized lung tumour. Group 3-SOI was characterized by high perioperative mortality,
initially localized lung tumours, and local evolution. Group 4-TOI was associated with low perioperative mortality, initially
localized lung tumours, loco regional extension, and distant metastasis. CTCs were detected in 83% of nude mice bearing
subcutaneous or orthotopic NSCLC tumours.
Conclusions: Transpleural orthotopic injection of A549-luc cells in nude mouse lung induces localized tumour, followed by
lymphatic extension and specific mortality, and allowed the first time identification of CTCs in a NSCLC mice model.
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Introduction
Non-small cell lung cancer (NSCLC) is the leading cause of
cancer-related mortality worldwide. Despite numerous clinical
trials of preclinically promising drugs, no major outbreak has been
made in NSCLC management in the last decades. Although there
is strong evidence based medicine supporting the clinical use of
cytotoxic, around 3 types of agents have shown consistent but
limited efficacy (platinum, taxanes, gemcitabine). More recently,
targeted therapies have waived important hopes given their ability
to directly hit cancer cell specific survival mechanisms. In sharp
contrast with the robustness of the underlying biological rational,
clinical translational of this knowledge into clinical benefit still
remains challenging since targeted therapies showed only a
marginal survival benefit when considering the whole NSCLC
patients population [1–4]. After these initial trials, retrospective
molecular analyses of tumor tissue led to the definition of
subgroups of patients that favourably respond to investigational
treatments, with management of certain cancers being revolution-
ized [5]. Among patients with NSCLC who receive erlotinib, the
presence of an EGFR mutation increased responsiveness to the
agent [6,7], but concerned only 16% of patients [8]. More
recently, the inhibition of anaplasic lymphoma kinase (ALK) has
been reported to result in tumour shrinkage or stable disease in
most patients with NSCLC harbouring EML4-ALK fusion genes,
but concerned only 2 to 7% of NSCLC [9]. However, in the
meantime, considerable efforts have been spent in clinical trials
testing active treatments on resistant tumors [2,3,10–12].
The discrepancy between the values of the clinical rationale, the
amount of preclinical data on one hand and the low output of their
transfer in clinical trials suggest that the relevance of preclinical
models may be questioned. Especially, preclinical testing should
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Current in vivo preclinical models are not reflecting the steps of
malignant progression from normal tissue to precancerous lesion
and then to cancer (localized and then metastatic). Ideal model
should mimic the natural history of human cancer, in order to
improve our understanding of cancer pathogenesis, predict the
efficacy of the investigated treatment and identify which treatment
will fit to which patient before the design of clinical trials. In this
context, xenografts models remain the cornerstones of preclinical
experiments and will gain from which technical improvements,
along with the recent development of computer-assisted drug
design, computer modeling, and genetically engineered animals
[14]. Human NSCLC xenografts may be implanted into
immunodeficient animals either subcutaneously (SC) or orthotop-
ically. In one hand, SC xenografts of lung cancer are easy to
perform and to follow, but lack relevance regarding (i) the natural
history of cancer due to absence of lymphatic or metastatic
extension, and (ii) the prediction of drug efficacy in clinical trials as
witnessed by the high proportion of negative clinical trials [13]. In
the other hand, orthotopic models of lung cancer are technically
more challenging, do not always mimic the natural history of lung
cancer, but raise considerable hope regarding drug screening [15].
The recent increase in our understanding in the cross talk of the
tumor stroma [16–18] and its involvement in drug resistance,
metastasis, immune escape, angiogenesis strongly suggests that
orthotopic models should provide valuable information that one
could not obtain from sub-cutaneous models.
Considering thoracic tumors, the technical challenge is to grow
‘‘lung tumor cells within the chest’’. Several techniques may be
used to this aim, including intra tracheal administration [19] or
percutaneous orthotopic injection [20] of NSCLC cells in solution,
and surgical orthotopic implantation of subcutaneously grown
tumour originating from NSCLC cell line [21]. Intratracheal
administration is associated with diffuse initial spreading of the
cells to both lungs, interfering with progression and lung metastasis
process, therefore favouring percutaneous and surgical models.
However, technical feasibility and natural history of these two
models have never been compared. This study sought to compare
and refine these two orthotopic xenografts models of lung cancer,
with the ultimate goal to reproduce human NSCLC progression,
from initially localized intraparenchymatous tumor, to metastasis
development and general worsening. For this purpose, we
compared four xenografts models, including SC injection used
as control, percutaneous orthotopic injection and surgical
orthotopic implantation as previously described, and transpleural
orthotopic injection as a new model. To allow longitudinal follow
up of tumor progression and further evaluation of treatment
efficacy, we used a cell line transfected with luciferase and
performed in vivo bioluminescent imaging. Feasibility was assessed
by perioperative mortality and engraftment rate. Clinical rele-
vance was assessed by initial intra parenchymatous location, loco-
regional extension, metastatic extension, median survival and
histological aspect. In an exploratory analysis, identification of
Circulating tumor cells (CTCs) was performed using the
CellsearchH assay (Veridex LLC, USA).
Materials and Methods
Cell line
Human A549 lung adenocarcinoma cell line stably transfected
with luciferase (A549luc) was purchased from Caliper Lifesciences
Corp. Cells were cultured in complete medium, consisting of 10%
(v/v) fetal bovine serum, 2 mmol L-glutamine, and 50 units/mL
penicillin-streptomycin in RPMI (all from Invitrogen). Cells were
grown at 37uC and 5% CO2 in an incubator, tested as mycoplasm
free using a PCR mycoplasma detection kit (MycoProbe, R&D
Systems, MN, USA), and tested as luciferase positive using direct
application of 2 mL of a 150 mg/ml solution of luciferine (Firefly
Luciferin, Caliper Lifescience Corp, USA), followed by immediate
bioluminescent imaging (IVIS system, Caliper Lifescience Corp,
Figure 1a).
Animals
Six-week-old female athymic mice were purchased from Janvier
(Elevage Janvier, Mayenne, France), and kept in appropriate
conditions. Once arrived in our animal facility, mice were divided
in 4 groups, underwent xenografts implantation following the
protocols described below (Figure 1b), and subsequent biolumi-
nescent imaging. Per procedure mortality rate, engraftment rate,
locoregional and metastatic progression were determined. The end
of the experiment was defined as cachexia, dyspnea, or clinical
worsening. Animals were then humanely killed. Primary tumour,
lungs, and mediastinal lymph nodes were surgically harvested,
fixed using a formalin-free, water-based concentrate (Finefix,
Milestone S.r.l., Sorisole, Italy), and embedded in paraffin.
Histological examination was then performed. Cancer-related
mortality was assessed. All animal experiments were approved by
the local Ethics Committee (CEEA IRCIV/IGR nu26, registered
with the French Ministry of Research), and were in compliance
with the European Directive 86/609/CEE and French laws and
regulation.
Subcutaneous (SC) injection (group 1 - SC)
A solution of 3610
6 A549luc cells in 200 mL of culture medium
was injected subcutaneously into the left flank region of the
animals (n=15), using 1-mL tuberculin syringes with 30 G
hypodermic needles (Becton Dickinson, NJ, USA).
Percutaneous orthotopic injection (group 2 - POI)
Animals (n=30) were anesthetized using isoflurane and putted
in a position of dorsal decubitus. Under radiographic control,
3610
6 A549luc cells in a solution containing 30 mL of culture
medium, 10 mL of contrast medium (Omnipaque 300, GE
Healthcare SA, France), and 10 mL of mouse sarcoma extracel-
lular matrix (Matrigel, BD Biosciences, NJ, USA) were injected
percutaneously into the left lung of the animals using 1-mL
tuberculin syringes with 30 G hypodermic needles (Becton
Dickinson, NJ, USA). Mice were then allow to rest on a heating
carpet until fully recover.
Surgical orthotopic implantation (group 3 - SOI)
As a first step, 3610
6 A549luc cells were injected subcutane-
ously into the flank region of 3 donor animals. Once SC tumours
reached 50 mm3, tumours were harvested and subdivided into
1m m
3 pieces constituting tumour grafts. Recipient animals
(n=25) were anesthetized using intraperitoneal injection of
xylazine (20 mg/kg) and ketamine (100 mg/kg), intubated using
a 22 G i.v catheter, mechanically ventilated (stroke volume
200 mL, respiration rate=120 strokes/min, Ventilator Minivent
Type 845, Harvard Apparatus, MA, USA) and putted in a
position of right lateral decubitus. A 2-cm skin incision was made
below the left scapula and a sharp dissection of the chest muscles
was performed, in order to expose the costal layer. A 0.5 cm
intercostals incision between the third and fourth costa on the
chest wall was made, and the chest wall was opened. The left lung
was taken up by a forceps, clamp with a carotid clamp (Scanlan
International, MN, USA), incised with surgical knife, and the
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incision of the lung parenchyma was closed with surgical glue
(Bioglue, Gamida, France). The incision of the chest wall was
closed by a 4-0 polypropylene suture (Prolene, Ethicon Inc, USA).
Mice were then allow to rest on a heating carpet until fully
recover.
Transpleural orthotopic injection (group 4 - TOI)
Animals (n=30) were anesthetized using intraperitoneal
injection of xylazine (20 mg/kg) and ketamine (100 mg/kg), and
putted in a position of right lateral decubitus. A 2-cm skin incision
was performed below the left scapula, and a sharp dissection of the
chest muscles was performed, in order to expose the costal layer.
On observing the left lung motion through the pleura, 3610
6
A549luc cells in a solution containing 10 mL of culture medium,
and 10 mL of mouse sarcoma extracellular matrix (Matrigel, BD
Biosciences, NJ, USA) was directly injected through the intercostal
space into the lung to a depth of 3 mm using a 29 G needle
permanently attached to a 0,5 mL insulin syringe (Becton
Dickinson, NJ, USA). The skin incision was closed by a 4-0
polypropylene suture (Prolene, Ethicon Inc, USA). Mice were then
allow to rest on a heating carpet until fully recover.
Bioluminescent imaging
Bioluminescent imaging was detected from luciferase expressing
A549 cells (A549luc) after implantation of the xenografts into
mice. Luciferin (Firefly Luciferin, Caliper Lifescience Corp, USA)
was used as the substrate for the luciferase expressing tumour cells
and injected intra peritoneally at a concentration of 150 mg/kg in
PBS, 15 minutes before imaging. Mice were then anesthetized
using 2% isofluorane and imaged using a cooled CCD camera
(IVIS system, Caliper Lifesciences Corp, USA). Exposure times
ranged from 1 minute to 1 second. Images were quantified as
photons/s using the Living Image software (Caliper Lifesciences
Corp, USA). Bioluminescent imaging was performed at day one,
then weekly, and then immediately before sacrifice. Xenograft
implantation rate was defined as the number of primary tumour
on imaging 2 weeks after grafting divided by the number of animal
alive after the procedure. Subsequent locoregional extension,
lymphatic and haematogenous metastasis rates were determined
during a 2-month follow up, and confirmed by pathologic
examination at the end of the experiments.
Identification of CTCs
To further characterize SC and transpleural injection models,
we sought to identify CTCs in these models, using 2 additional
groups. In the CTC group 1, athymic nude mice underwent SC
injection of A549luc cells in both flanks (n=6). In the CTC group
2, animals underwent general anesthesia, chest wall incision, and
transpleural injection of cells in the parenchyma of the left lung
(n=15). After 2 weeks, bioluminescent imaging was performed,
and tumour-bearing animals were identified. During the third
week, 6 tumour-bearing animals from each group were randomly
chosen and anesthetized. A venous blood puncture of 600 mL was
performed in the cavernous sinus and was tested for CTC using
the CellSearchH system and a modified protocol based on the
Figure 1. Study flowchart. a. A549 cells stably transfected with luciferase were tested by direct application of serum saline (left side, control) or
luciferine (right side), and analysed after optical imaging (Time 1 min after addition of luciferine, exposure 1 min, bin medium). b. Animals were
divided in 4 groups, subcutaneous injection (group 1-SC), percutaneous orthotopic injection under radiographic control (group 2-POI), surgical
orthotopic implantation after orotracheal intubation and thoracotomy approach (group 3-SOI), and transpleural orthotopic injection after costal layer
surgical exposure (group 4-TOI).
doi:10.1371/journal.pone.0026073.g001
Bioluminescent Orthotopic Mouse Models of NSCLC
PLoS ONE | www.plosone.org 3 October 2011 | Volume 6 | Issue 10 | e26073CellSearchH Epithelial Cell kit (Veridex LLC, USA). Briefly, to
identify human CTCs in mouse blood, each 600 mL mice blood
samples was mixed with 7 mL of healthy human blood. Then,
each sample was automated enriched for cells expressing the
epithelial-cell adhesion molecule (EPCAM) with antibody-coated
magnetic beads, and cells were labeled with the fluorescent nucleic
acid dye 49,6-diamidino-2-phenylindole dihydrochloride (DAPI).
Fluorescently labeled monoclonal antibodies specific for leukocytes
(CD45–allophycocyan) and epithelial cells (cytokeratin 8,18,19-
phycoerythrin) were used to distinguish epithelial cells from
leukocytes. Cell Enrichment and labeling were performed using
the CellSearchH Autoprep. The identification and enumeration of
CTCs was performed using the CellSearchH Analyzer II. CTCs
were defined as nucleated cells lacking CD45 and expressing
cytokeratin 8, 18, 19. As a negative control, a solution containing
600 mL of non-tumor bearing mouse blood and healthy human
blood was analysed. As a positive control, 50 and 500 A549luc
cells were analysed in a solution containing 600 mL of medium and
7 mL of healthy human blood.
Statistical analysis
Normally distributed continuous variables were expressed as
means 6 standard deviation, and compared with unpaired t-tests.
Categorical data were expressed as counts and proportions, and
compared with Fisher exact tests. All tests were 2-sided and a p-
value,.05 was considered significant. All data analyses were
performed with the free R software (http://www.r-project.org, R
Foundation for Statistical Computing, Vienna, Austria).
Results
Feasibility
Feasibility was assessed by determination of perioperative
mortality and engraftment rate. The perioperative mortality was
null in group 1-SC used as a control, and significantly higher in
group 3-SOI (60%, p,0.001) but not in groups 2-POI (6%,
p=.79) or 4-TOI (3%, p=.72). Assessing the effect of a learning
curve on the perioperative mortality of group 3-SOI, we observed
a non significant decrease in the mortality between the first 10
animals and the former 15 animals (mortality 80% vs 47%,
respectively, p=.21). No significant difference was observed
between groups 2-POI and 4-TOI regarding the perioperative
mortality rate (p=.99, Table 1). The engraftment rate was 100%
in group 1-SC used as a control, and significantly lower in group
2-POI (68%, p=.037), group 3-SOI (60%, p=.034) and group 4-
TOI (65%, p=.027). No significant difference was observed
between the 3 experimental groups regarding the engraftment rate
(p=.90, Table 1).
Clinical relevance
Clinical relevance was assessed by location of the initial tumor,
imaging of tumor extension, survival analysis and histological
examination. The initial tumor was confined to the SC tissue in
group 1-SC and to the lung parenchyma in group 3-SOI. In group
2-POI, 53% of the animals underwent pleural seeding during
percutaneous orthotopic injection and developed initial loco
regional extension to both pleurae. As the goal of this study was
to obtain an intrapulmonary localized NSCLC model, this
immediate pleural seeding disqualified the technique. In group
4-TOI, the tumour was initially confined to the lung parenchyma
(Table 1, Figure 2a and 2b). Bioluminescent imaging found
irregular curves in group 1-SC and 3-SOI, with high inter
individual and chronological variations. No animal developed
locoregional or metastatic extensions during follow up. In group 2-
POI, no bioluminescence curve was plotted because of perioper-
ative pleural seeding. One animal developed bone metastasis. In
group 4-TOI, bioluminescent imaging found a regular, exponen-
tial curve after day 21. Seven percents of the animals developed
locoregional extension to homolateral pleura as an evolution of the
primary tumour. One animal developed bone metastasis (Table 1,
Figure 2a). Survival analysis revealed that median survival was
not achieved after a follow up of 2 months in group 1-SC and 3-
SOI. In group 2-POI, no survival curve was plotted because of
perioperative pleural seeding. In group 4-TOI, median survival
was 40 days (Table 1, Figure 2c). Histological examination
revealed SC round tumours with a regular shape, high proportion
of undifferentiated carcinoma, few capsular ruptures, and few
vascular or lymphatic emboli in group 1-SC. In group 2-POI,
regular intraparenchymatous tumors were obtained, with a low
proportion of undifferentiated carcinoma, a high number of
capsular ruptures, and vascular or lymphatic emboli. In group 3-
SOI, irregular intraparenchymatous tumors were obtained, with a
low proportion of undifferentiated carcinoma (+), capsular
ruptures (++) and a high number of vascular or lymphatic emboli.
The findings were similar in group 4-TOI and group 2-POI
(Figure 3, Table 2).
Identification of CTCs
Xenograft implantation rates were 100% in CTC group 1 (SC,
n=6) and 60% in CTC group 2 (TOI, n=9). Three CellsearchH
assays were performed in each control group, and 6 CellsearchH
assays were performed in each experimental group. Negative
controls demonstrated zero or one CD452, DAPI+, CKPE+ cell
per assay (data not shown). Positive controls demonstrated a
correlation between the number of tumor cells in solution and the
CellsearchH CTC count (Figure 4a and 4b). In CTC group 1-
SC, 5 assays (83%) were positive for CTCs detection (CTCs level
Table 1. Per-procedure mortality, tumor engraftment, and tumor extension rates.
Number
of animals
(n)
Per-procedure
mortality rate
(n)
Implantation
rate
(n)
Loco-re ´gional
invasion
(n)
Metastasis
(n)
Subcutaneous injection (group 1) 15 0 100% (15) - -
Percutaneous orthotopic injection (group 2) 30 6% (2) 68% (19) 53% (15) 3% (1)
Surgical orthotopic implantation (group 3) 25 60% (15) 60% (6)** - -
Transpleural orthotopic injection (group 4) 30 3% (1) 65% (19) 7% (2) 3% (1)*
*Bone metastasis.
**n=1 false positive (infection); n=2 false negatives.
doi:10.1371/journal.pone.0026073.t001
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positive for CTCs detection (CTCs level range 2–21, mean
9.569.35). All together, 3 weeks after tumour implantation, CTCs
were detected in 83% of nude mice bearing either SC or orthotopic
NSCLC tumours (Figure 4c and 4d). When comparing groups,
the difference in CTC levels showed a trend toward statistical
significance (p=.058, Figure 4c, Table 2).
Discussion
Tumor implantation site and method impacts tumor
development and kinetics
Comparing SC, percutaneous orthotopic injection and surgical
orthotopic implantation models with intend to refine the follow up
of tumour progression using bioluminescent imaging, we faced the
limits of these models, including organ discrepancy (SC), frequent
pleural seeding (percutaneous orthotopic injection) and high
perioperative mortality (surgical orthotopic implantation). Fur-
thermore, none of these models allow a reliable follow up of
tumour progression using bioluminescent imaging. Therefore, we
developed a transpleural orthotopic injection model, combining
low perioperative mortality, reasonable engraftment rate, scarcity
of pleural seeding, and tumour progression with metastasis for
which tumor progression may be monitored by bioluminescent
imaging. Furthermore, this study allows identification of CTCs in
murine models of NSCLC for the first time to date. We believe
that besides functional imaging, the application at the preclinical
in vivo stage of CTCs will contribute to define biomarkers of
tumour burden and treatment efficacy in subsequent clinical trials.
SC xenografts models
SC xenografts from human-derived cell lines to immunodefi-
cient animals have been the gold standard of preclinical cancer
experiments for decades [14]. This model presented several
advantages, including technical feasibility (absence of anesthesia,
easy-to-perform injection) and tumor accessibility (direct measure-
ment of the SC tumor allowing longitudinal follow up). However,
SC models are limited by discrepancy between xenograft origin
Figure 2. Follow-up using bioluminescent imaging and survival curves. a. Evolution of the photons count (expressed as 10
6 photons/s) over
time, from day 0 (implantation) to day 63 (end of the bioluminescent follow up). For each time, the mean and standard deviation of the animals alive
are reported. In group 2-POI, percutaneous injection led to pleural seeding in 53% of the cases, as postoperative X-ray showed contrast agent in
either left pleural space, right pleural space (anatomical continuum), or both. b. Representative evolution of the bioluminescent signal, from day 14 to
day 42. In group 2-POI, pleural seeding created a signal located at the right basis of the thorax, contradicting with the primary goal of this study. No
subsequent follow-up as been performed for this group. c. Survival curve from the time of tumor implantation to 2 months using the Kaplan-Meier
method and 95% confidence interval bars. The 2-month survival is 100% in group 1-SC, 40% in group 3-SOI, and 65% in group 4-TOI.
doi:10.1371/journal.pone.0026073.g002
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paracrine signals, and therefore do not model Paget’s ‘‘seed and
soil’’ theory [22]. This discrepancy has been found to impact
tumour response to cytotoxic agents and radiation therapy [23,24]
and certainly impact the response to novel anticancer agents. This
discrepancy might be of critical importance in NSCLC, were
hypoxia and neoangiogenesis play a major role in tumor
progression [25], and occur differently in SC and intrathoracic
xenografts [26]. Last, only a minority of SC models disseminate
and progress to the metastatic stage, the absence of progression
from localized to metastatic stage through loco-regional lymph
node extension is therefore a major limitation of SC models while
the major cause (2/3) of cancer death is metastatic disease.
These differences have major implications regarding tumor
progression, with few circulating tumor cells and no metastasis in
our experiments, pointing a major limit to drug evaluation, with
two risks. The first risk is to push into the clinic a molecule or a
drug combination with little or no efficacy. As an example, the
combination of chemotherapy and EGFR inhibitors has proved
efficacy in SC models of NSCLC [27,28], but has never reached
significant efficacy in clinical trials including unselected NSCLC
patients upon EGFR status [3,10,29]. The second risk is to stop
the development of promising drugs. As an example, HIF-1alpha
antagonist PX-478 showed no measurable activity against NSCLC
SC xenografts, but inhibited progression and spread of orthotopic
human small cell lung cancer and lung adenocarcinoma in mice,
and is finally tested in phase 1 trial [30].
Altogether, these data suggest that SC xenografts are not fully
adequate for the preclinical study of NSCLC, and should only be
used and analyzed carefully. Similar conclusions have been drawn
from SCLC preclinical drug testing [31].
Previous orthotopic models
To take the influence of organ specificity and tumor micro
environnement into account, orthotopic models have been
progressively developed over the last 20 years, with the ultimate
goal to obtain a single intraparenchymatous lung tumor that
mimic the clinical situation and allow longitudinal follow up.
Intravenous [32], intrabronchial [33–35] and intrapleural admin-
istration [36,37] of lung cancer cell lines resulted in pleural, locally
advanced, or multiple synchronous tumors. Therefore, these
models may be interesting to study these particular situations,
but may not be extended to localized intrapulmonary NSCLC,
constituting the majority of NSCLC patients and the basis of
further tumor progression.
Genetically engineered mouse models (GEMMs) have also been
developed to study NSCLC in mice. These animals are usually
p53 mutated, favoring genetic instability and tumor formation,
and develop lung tumors driven by the EGFR [38], KRAS [39],
PIK3CA [40], BRAF [41] oncogenic activation or the presence of
Figure 3. Pathological examination. Surgical orthotopic implantation (Group 3) resulted in localized infiltrating tumors, whereas percutaneous
orthotopic injection (Group 2) and transpleural orthotopic injection (group 4) resulted in localized rounded nodules. Histological examination
revealed a high proportion of undifferentiated carcinoma in group 1-SC tumor, but a low proportion in the 3 experimental groups. Furthermore, the 3
experimental groups were associated with more capsule rupture and vascular emboli than group 1-SC.
doi:10.1371/journal.pone.0026073.g003
Table 2. Pathological examination and CTC levels.
Primary tumor
Undifferenciated
population
Capsular
rupture Emboli CTC
Subcutaneous injection (group 1) SC +++ + +
Percutaneous orthotopic injection (group 2) Lung+pleura + +++ +++ 2.5±1.76/animal
Surgical orthotopic implantation (group 3) Lung ++ + +
Transpleural orthotopic injection (group 4) Lung + +++ +++ 9.5±9.35/animal
doi:10.1371/journal.pone.0026073.t002
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may be observed in mouse strains carrying oncogenic alleles of
KRAS that can be activated only on a spontaneous recombination
event in the whole animal [43], or after KRAS sporadic activation
through Cre-lox mediated somatic recombination after adenoviral
mediated delivery of Cre recombinase in lung epithelia [39]. Both
models allow the development of KRAS-mutated lung cancer in a
short period of time. However, these models are limited by their
distance to clinical situation, as mutations of one or two oncogenes
or tumor suppressor genes are far from the multi step progression
of lung cancer occurring on underlying chronic inflammation.
Furthermore, GEMM models result in hundreds of primary
NSCLC in the same period of time those are difficult to follow and
to quantify during preclinical testing and non-invasive imaging.
Despite these drawbacks, GEMM have the advantage to refine the
definition of oncogenes and to take immune response into account.
Recent studies have reported that GEMM may be of interest when
studying the efficacy of common NSCLC treatments [44].
Surgical implantation of NSCLC fragment into the lung of
immunodeficient mice via thoracotomy was first reported in 1992
[21,45,46]. Tumor fragment came from primary fresh tumors or
subcutaneously-grown tumors developed after NSCLC cells
injection. Tumor fragment were inserted into the lung parenchy-
ma, on the visceral pleura, or on the parietal pleura, according to
the disease extension aimed for. Per procedure mortality was
below 10%, engraftment rates ranged between 60 and 100%, but
not systemic metastasis was observed. The same model was then
developed in rat [47] and confirmed using primary cultured cells
from surgical-resected NSCLC in SCID mice [48]. Addition of
GFP to implanted tumor allow in vivo imaging of orthotopic
xenografts development, and metastatic extension to mediastinal
lymph nodes, controlateral lung, and bone [49–52]. However,
these experiments are technically difficult, require specialized
laboratory and dedicated manpower, and despite encouraging
preliminary results [53], have not been generalized in preclinical
NSCLC research to date.
Figure 4. Identification of circulating tumor cells. a. Representation of the staining of circulating cells using the CellsearchH assay. CTC are
defined as CD452, DAPI+, and CKPE+ cells. - Upper line: as a positive control, 50 and 500 A549luc cells were analysed in a solution containing 600 mL
of medium and 7 mL of healthy human blood. Here, as an example, both CD452, DAPI+, CKPE+ cells are tumor cells. - Bottom line: representation of
the results of the experimental groups. Here, as an example, this CD452, DAPI+, CKPE+ cell is a CTC. b. Correlation between the Cellsearch H CTC
count and the number of tumor cells in solution. As controls, 0 (negative control), 50 and 500 (positive controls) A549luc cells were analysed in a
solution containing 600 mL of medium and 7 mL of healthy human blood. This experiment demonstrated a correlation between the CellsearchH CTC
count and the number of tumor cells in solution (R
2=.99857). c. Number of CTC according to the experimental group, CTC group 1 (SC) or CTC group
2 (orthotopic). The overall positivity of the Cellsearch H assay is comparable in both groups (83%), with a trend toward more CTC in the orthotopic
rather than in the subcutaneous model. d. Representation of the bioluminescent signal and number of CTC detected in each of the 12 animals.
doi:10.1371/journal.pone.0026073.g004
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bioluminescent imaging
Orthotopic injection of NSCLC cells in nude mice has been
developed to overcome the technical difficulties of thoracotomy
[20,54,55]. This technique is technically feasible with a low
mortality rate and a high engraftment rate, with 2 limits. The first
limit is the impossibility to predict perioperatively if the tumor will
be localized to the lung parenchyma or if there is a pleural seeding
leading to a locally advanced tumor. Therefore, to obtain a single
tumor limited to the lung parenchyma, we used a high number of
cells in a small volume of medium and add some matrix of mouse
sarcoma, improving the solution anchorage to the lung parenchy-
ma. We injected this solution trans pleurally, under direct vision of
the lung motion through the intercostal space, combining
technical feasibility (absence of orotracheal intubation and
mechanical ventilation) and high precision.
The second limit is the requirement of a longitudinal follow up
using micro CT in the absence of fluorescent or bioluminescent
imaging. MicroCT has limited spatial resolution and is available
only in a limited number of facilities. Therefore, we used
luciferase-transfected NSCLC cell line to allow in vivo biolumi-
nescent imaging. This technique has already been reported in a
percutaneous orthotopic model with pleural seeding [56], and has
now been applied successfully to transpleural model with localized
intra parenchymatous NSCLC model.
This xenogenic, orthotopic and bioluminescent model allowed
the first time identification of CTCs in murine models of NSCLC.
CTCs are released into the bloodstream from tumors of epithelial
origin [57].
As haematogenous dissemination of tumor cells is the main
mechanism for distant metastasis, the assessment of cancer
patients’ blood is a highly desirable approach for detecting
systemic tumor cell spreading [58] and residual disease. CTCs
may be identified directly after automatic enrichment and
immunocytochemical detection (CellSearchH System) [59], mag-
netic bead enrichment and laser scanning cytometry (Maintrac
System) [60], microfluidic harvesting and molecular characteriza-
tion (CTC-Chip) [61], or membrane filter device (Isolation by Size
of Epithelial Tumor cells – ISET) [62]. The CellSearchH system is
the most available, and is now FDA-approved in breast, colorectal,
and prostate cancers. This new application to NSCLC preclinical
model could be of significant interest to study the role of CTCs in
NSCLC progression and response to new therapeutic strategies.
Study limits and future developments
Our study has important limitations regarding the use of
immunodeficient animals and the heterogeneous genetic back-
ground of the xenografts, as the validity of xenograft models
remains disputed by the compromised of anti tumour immunity
and the absence of clearly characterized molecular abnormalities
in comparison with GEMM. Therefore, we believe that the next
step refinement in preclinical models in vivo could take advantage
of the in situ implantation of tumour fragments or cells into the
lung as well as the advantage of murine tumour models (immune
response and GEMM derived tumours).
The application of current NSCLC treatments to both models
would ultimately determine the most relevant model for preclinical
studies. The value and the additional benefit of these novel
approaches will have to be compared not only to other techniques
available but also in terms of go/no go decision making value
toward the clinical stage. Our vision is that functional imaging and
biological pre and per treatment parameters such as CTCs may
also contribute to demonstrate the improvement in clinical value
of these approaches. In particular, we propose that orthotopic
implantation of GEMM derived lung tumours into the lung could
be an optimal strategy to evaluate tumour immunity and to
monitor the efficacy of therapies at the non metastatic, locally
advanced tumour stage (i.e. surgery and/or radiotherapy com-
bined to novel agents).
Conclusion
The tumour microenvironment plays a major role in promoting
tumour growth [63]. In xenografts models, tumour localization is
important regarding sensitivity to chemotherapy [23], and will be
critical regarding sensitivity to targeted therapies, as suggested by
the involvement of integrin in the interactions between the tumour
and its environment, and subsequent cross talks with targeted
pathways. For these reasons, we have developed a murine
intrapulmonary model of human non-small cell lung cancer,
associated with low peri operative mortality, high engraftment
rate, locoregional grow, and development of metastasis. This
model allows the first time identification of a high number of
circulating lung tumour cells in mice bearing human xenografts of
NSCLC.
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